Xlife Sciences AG (XLS DE): Breakthrough in Drug Development

First available holistic medical drug to treat Covid-19 and flu viruses

ZURICH, SWITZERLAND – EQS Newswire – 10 June 2021 – As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH
has developed a revolutionary and holistic therapeutic approach to treat both
SARS-CoV-2 and flu viruses. The patented active substance ProcCluster(R)
reduces the viral load by 90% and acts against infection-related inflammatory
processes without developing a resistance. It is already used on humans.

The active pharmaceutical ingredient ProcCluster(R) developed by inflamed pharma GmbH is membrane permeable and is based on the active ingredient procaine. It acts both locally as well as systemically and is characterized by a wide range of applications in inflammatory diseases. ProcCluster(R) is already used for various prescription drugs for humans. In various case studies, renowned medical doctors have now been able to successfully demonstrate the effectiveness in the treatment of Covid-19 and Long-Covid patients. In studies with various cell lines, especially lung cells, the active ingredient was able to reduce the viral load by 90% in an early phase and effectively inhibit inflammation in a later phase. These effects can be transferred to other RNA viruses.

Oliver R. Baumann, CEO of Xlife Sciences AG, comments: “ProcCluster(R)
has enormous market potential because, in contrast to other active ingredients,
both the inflammatory processes and the viral load in the body are
significantly reduced. This means that it can be used at different points in
time during the course of the Covid-19 disease”. It is of inestimable
value that this active ingredient is already produced by inflamed pharma GmbH
in high quality at low cost. “Another key advantage compared to vaccines
and antibodies is that ProcCluster(R) does not lead to resistance development
and can also be used against virus mutants”, continues Baumann. In
addition, ProcCluster(R) has a stimulating effect on the microcirculation,
which is particularly important for Long-Covid patients. So far, no negative
side effects have been observed either.

According to the management of Xlife, they are already in various discussions with possible industrial partners in order to have ProcCluster(R) industrially manufactured. The aim is for the active ingredient to be licensed out as quickly as possible.

The issuer is solely responsible for the content of this announcement.